Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR

Scandinavian Journal of Immunology

Volumn 71, Issue 6, 2010, Pages 393-402

  Drexler, S K ^a   Wales, J ^a   Andreakos, E ^b   Kong, P ^a   Davis, A ^a   Garlanda, C ^c   Mantovani, A ^c,d   Hussell, T ^e   Feldmann, M ^a   Foxwell, B M J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD86 ANTIGEN; DEATH RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INFLUENZA; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TH1 CELL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, INTERLEUKIN-1; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS; VACCINATION;

EID: 77952265563     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02392.x     Document Type: Article

References (30)

1. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008 99 : 363 407.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005 5 : 296 306.
3. Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 2006 177 : 8410 8421.
4. Wales J, Foxwell B, Feldmann M. Targeting intracellualr signalling: a novel approach to vaccination. Expert Rev Vaccines 2007 6 : 971 980.
5. Takeshita F, Tanaka T, Matsuda T et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006 80 : 6218 6224.
6. Andreakos E, Williams RO, Wales J, Foxwell BM, Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006 103 : 14459 14464.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004 4 : 499 511.
8. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006 7 : 1074 1081.
9. Andreakos E, Sacre SM, Smith C et al. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004 103 : 2229 2237.
10. Burns K, Martinon F, Esslinger C et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998 273 : 12203 12209.
11. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. J Immunol 2001 167 : 5895 5903.
12. Humphreys IR, Edwards L, Snelgrove RJ, Rae AJ, Coyle AJ, Hussell T. A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection. Eur J Immunol 2006 36 : 2928 2938.
13. Yamazaki T, Nagata K, Kobayashi Y. Cytokine production by M-CSF- and GM-CSF-induced mouse bone marrow-derived macrophages upon coculturing with late apoptotic cells. Cell Immunol 2008 251 : 124 130.
14. Foxwell B, Browne K, Bondeson J et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998 95 : 8211 8215.
15. Andreakos E, Smith C, Monaco C, Brennan FM, Foxwell BM, Feldmann M. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 2003 101 : 983 991.
16. Bondeson J, Brennan F, Foxwell B, Feldmann M. Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent. J Rheumatol 2000 27 : 2078 2089.
17. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985 314 : 537 539.
18. Sacre SM, Drexler SK, Andreakos E, Feldmann M, Brennan FM, Foxwell BM. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis 2007 66 (Suppl. 3 iii81 6.
19. Polentarutti N, Rol GP, Muzio M et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 2003 14 : 211 218.
20. Garlanda C, Riva F, Polentarutti N et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004 101 : 3522 3526.
21. Wald D, Qin J, Zhao Z et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003 4 : 920 927.
22. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005 280 : 25233 25241.
23. Into T, Inomata M, Nakashima M, Shibata K, Hacker H, Matsushita K. Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses. Mol Cell Biol 2008 28 : 1338 1347.
24. Xiao H, Gulen MF, Qin J et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007 26 : 461 475.
25. Lech M, Kulkarni OP, Pfeiffer S et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008 205 : 1879 1888.
26. Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003 197 : 7 17.
27. Fujikado N, Saijo S, Yonezawa T et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat Med 2008 14 : 176 180.
28. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002 76 : 6652 6659.
29. Escors D, Lopes L, Lin R et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008 111 : 3050 3061.
30. Wales JR, Baird MA, Davies NM, Buchan GS. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy. Vaccine 2005 23 : 2339 2341.